E
Apellis Pharmaceuticals, Inc.
APLS
$19.42
$0.633.35%
E
Sell
7/26/2024Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index, total return index and valuation index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
7/11/2024Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
E
Sell
10/4/2023Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E+ from D- on 10/4/2023 due to a large decline in the total return index and volatility index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E+ from D- on 10/4/2023 due to a large decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/22/2023Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 2/22/2023 due to a large increase in the growth index. Earnings per share increased from -$1.7527 to -$1.5004, operating cash flow increased 8.85% from -$154.42M to -$140.74M, and total revenue increased 2.75% from $22.06M to $22.66M.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 2/22/2023 due to a large increase in the growth index. Earnings per share increased from -$1.7527 to -$1.5004, operating cash flow increased 8.85% from -$154.42M to -$140.74M, and total revenue increased 2.75% from $22.06M to $22.66M.
D
Sell
2/8/2023Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, solvency index and valuation index. The quick ratio declined from 6.94 to 6.38.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, solvency index and valuation index. The quick ratio declined from 6.94 to 6.38.
D
Sell
5/5/2022Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index, solvency index and valuation index. Debt to equity declined from 0.97 to 0.42.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index, solvency index and valuation index. Debt to equity declined from 0.97 to 0.42.
D
Sell
4/20/2022Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
3/2/2022Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D from D+ on 3/2/2022 due to a major decline in the growth index, valuation index and volatility index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D from D+ on 3/2/2022 due to a major decline in the growth index, valuation index and volatility index.
D
Sell
11/9/2021Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D+ from D- on 11/9/2021 due to a major increase in the solvency index, growth index and total return index. Total revenue increased 806.9% from $623 to $5.65M, EBIT increased 34.12% from -$194.29M to -$128M, and debt to equity declined from -2.76 to -3.38.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D+ from D- on 11/9/2021 due to a major increase in the solvency index, growth index and total return index. Total revenue increased 806.9% from $623 to $5.65M, EBIT increased 34.12% from -$194.29M to -$128M, and debt to equity declined from -2.76 to -3.38.
D
Sell
11/8/2021Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D+ on 11/8/2021 due to a significant decline in the total return index and volatility index.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D+ on 11/8/2021 due to a significant decline in the total return index and volatility index.
D
Sell
8/10/2021Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D+ from D on 8/10/2021 due to a significant increase in the total return index, growth index and valuation index. Operating cash flow increased 16.06% from -$153.31M to -$128.69M.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D+ from D on 8/10/2021 due to a significant increase in the total return index, growth index and valuation index. Operating cash flow increased 16.06% from -$153.31M to -$128.69M.
D
Sell
5/1/2020Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the solvency index, total return index and valuation index. The quick ratio increased from 5.35 to 12.75, and debt to equity declined from 4.24 to 0.57.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the solvency index, total return index and valuation index. The quick ratio increased from 5.35 to 12.75, and debt to equity declined from 4.24 to 0.57.
D
Sell
11/7/2019Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 11/7/2019 due to a decline in the growth index, efficiency index and solvency index. Debt to equity increased from 0.05 to 1.02, operating cash flow declined 34.31% from -$39.91M to -$53.6M, and EBIT declined 10.2% from -$63.48M to -$69.95M.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 11/7/2019 due to a decline in the growth index, efficiency index and solvency index. Debt to equity increased from 0.05 to 1.02, operating cash flow declined 34.31% from -$39.91M to -$53.6M, and EBIT declined 10.2% from -$63.48M to -$69.95M.
D
Sell
8/2/2019Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 8/2/2019 due to a large increase in the total return index, volatility index and efficiency index.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from D- on 8/2/2019 due to a large increase in the total return index, volatility index and efficiency index.
D
Sell
11/14/2018Downgrade
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 11/14/2018 due to a substantial decline in the volatility index, efficiency index and valuation index. Total capital declined 13.05% from $256.31M to $222.86M, and net income declined 7.91% from -$33.33M to -$35.97M.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to D- from D on 11/14/2018 due to a substantial decline in the volatility index, efficiency index and valuation index. Total capital declined 13.05% from $256.31M to $222.86M, and net income declined 7.91% from -$33.33M to -$35.97M.
D
Sell
3/2/2018Upgraded
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from E on 3/2/2018 due to a large increase in the total return index.
Apellis Pharmaceuticals, Inc. (APLS) was upgraded to D from E on 3/2/2018 due to a large increase in the total return index.
E
Sell
2/6/2018None
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E from U on 02/06/2018.
Apellis Pharmaceuticals, Inc. (APLS) was downgraded to E from U on 02/06/2018.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
